Tag: innate
Innate pharma: Progress in a hematology trial
Receive the value of the day for free every morning The data collected is essential for this processing and is intended for the relevant services of BFM Bourse and, where…
Innate Pharma: IPH45 data presented at AACR – 04/10/2024 at 07:42
(CercleFinance.com) – Innate Pharma announces that the first preclinical data relating to IPH45, its exatecan-based antibody-drug conjugate (ADC), were presented at the 2024 annual meeting of the American Association for…
Innate Pharma: cash horizon extends until end of 2025
(AOF) – On the occasion of the presentation of its 2023 results, Innate Pharma specifies that its cash position was 102.3 million euros as of December 31, 2023 – this…
Innate Pharma: license option exercised by Sanofi – 12/19/2023 at 08:18
(CercleFinance.com) – Innate Pharma and Sanofi announce that Sanofi has exercised its licensing option for an NK Cell Engager program in solid tumors, originating from Innate’s ANKET platform, in accordance…
Innate Pharma: change of management
(AOF) – Innate Pharma, a biotech specialist in improving the treatment of cancers using innovative therapeutic antibodies exploiting the immune system, announces that Mondher Mahjoubi has resigned from his position…
Innate Pharma: resignation of the chairman of the management board
(CercleFinance.com) – Innate Pharma announces that Mondher Mahjoubi has resigned from his position as Chairman of the Management Board, effective January 2024, to join a large pharmaceutical group. Hervé Brailly,…
Innate pharma: Positive final results for TELLOMAK
Receive the value of the day for free every morning The data collected is essential for this processing and is intended for the relevant services of BFM Bourse and, where…
Innate Pharma: a lower tone
By Claude Leguilloux Published on 11/15/2023 at 2:28 p.m. (Boursier.com) — Innate Pharma fell 0.4% to 2.25 euros…
Innate Pharma: cash flow horizon in the 2nd half of 2025
(CercleFinance.com) – The biopharmaceutical company Innate Pharma displays cash, cash equivalents and financial assets amounting to 121.9 million euros as of September 30, 2023, with an expected horizon during the…
Innate Pharma: three results presented at the ASH congress in December
(AOF) – Innate Pharma (+4% to 0.028 euros) announces today that several abstracts, including an oral presentation, have been selected for the 65th annual meeting of the ASH (American Society…
Innate Pharma: ASH 2023, presentation of new clinical data for Lacutamab and SAR443579/IPH6101
By Hector Chaunu Published on 03/11/2023 at 08:22 a.m. (Boursier.com) — Innate Pharma SA announces that the following…
Innate Pharma: appointments to follow
HC Published on 10/27/2023 at 7:56 a.m. (Boursier.com) — Innate Pharma SA announces that members of…